2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

2961 Garp-dependent erythroid-to-myeloid trans-differentiation drives tumor immunosuppression

Maria Velegraki, MD, PhD, Jordan Krull, PhD2, Maryam Soltani-asl, PhD3, Jennifer E Vaughn, MD, MSPH4, Payton Weltge5, Cankun Wang, PhD6, Fiza Tarlochan7, Veronica Balatti, PhD8, Andrew Srisuwananukorn, MD9, Donna Bucci10, Anjun Ma11, Ann-Kathrin Eisfeld, MD12, Qin Ma, PhD13, Zihai Li, MD, PhD14
1 Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, United States, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
4 Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
5 Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, United States, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
8 Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
10 Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
11 Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, United States, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
12 Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
13 Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, United States, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
14 Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Introduction: During cancer progression, bone marrow-derived immature erythroid progenitor cells (EPCs) are released into circulation and home to sites of malignancy, where they exert potent immunosuppressive effects. These CD45+Ter119+ EPCs correlate with poor clinical outcomes, yet the molecular mechanisms underlying their suppressive function remain incompletely understood. We discovered that GARP (LRRC32), a cell-surface docking receptor for latent TGFβ, is strongly induced on tumor-associated EPCs. We sought to understand whether GARP is functionally required for the immunosuppressive capacity of these cells.
Methods: Erythroid-specific GARP knockout mice (EporCre;Lrrc32fl/fl) were generated and implanted subcutaneously with MB49 cells, a model that induces EPC accumulation. TME architecture was mapped using 10x Visium spatial transcriptomics (n=3 WT, n=4 KO) integrated with Vectra multi-plex immunofluorescence to define GARP+ EPC-enriched (G-EPC) regions. Single-cell gene expression was inferred using Thor. Analyses included immune deconvolution, differential expression, and ligand-receptor signaling (COMMOT). For in vitro transdifferentiation assays, splenic CD45+ EPCs from tumor-bearing mice were cultured with GM-CSF and IL-6 for 3 days. CD8+ TILs were profiled by spectral flow cytometry. Functional validation included tumor growth studies and adoptive co-transfer of antigen-specific CD8+ T cells with WT or KO EPCs.
Results: Splenic CD45+Ter119+ EPCs expanded 5-8-fold in MB49-bearing mice and upregulated GARP. Spatial transcriptomics integrated with Vectra immunofluorescence revealed the immune architecture around the G-EPC niches. Within these niches, erythroid lineage markers (Gata1, Klf1, Alas2) and myeloid/MDSC markers (S100a8, S100a9, Lcn2, Il1b) were co-elevated. Thor single-cell inference resolved gene expression at cellular resolution and suggested that erythroid and myeloid programs converged within the same individual cells, supporting erythroid-to-myeloid transdifferentiation as described by Long et al. (Cancer Cell 2022). DecoupleR analysis revealed that G-EPC niches displayed elevated HIF1α, Stat3, NFκB, and C/EBPβ activity, consistent with a hypoxic, inflammatory, and immunosuppressive microenvironment.
In GARP KO tumors, MDSC abundance dropped by 50%. TACCO deconvolution confirmed that MDSCs were the top differentially enriched cell type in WT within G-EPC regions. Mechanistically, GARP deletion collapsed the C/EBPβ-driven MDSC transcriptional program: S100a8 and S100a9 were 14-fold lower than WT (log2FC -3.8, padj<0.0000), with downregulation of Lcn2 (log2FC -2.9), Il1b (log2FC -2.2), Cxcl1/3, and Csf3. The C/EBP transcription factor balance was reversed: Cebpa was elevated while Cebpb was reduced. The canonical TGFβ pathway was also disrupted, with Smad4 3-fold lower in KO.
We then performed in vitro transdifferentiation assays. WT EPCs cultured with GM-CSF and IL-6 readily converted to CD11b⁺Gr-1⁺ myeloid cells, whereas GARP-KO EPCs failed to transdifferentiate, confirming that GARP is essential for the EPC-to-MDSC lineage switch.
Spectral flow cytometry revealed that GzmB+ effector CD8+ T cells increased 3-fold in KO tumors with elevated effector markers and reduced exhaustion. The TME signaling landscape shifted from stromal-adhesive and angiogenic pathways (Spp1-Itgav/Itgb1, Gas6-Axl, Angptl4-Cdh5) to cytotoxic/chemokine signals (Gzma-Pard3, Ccl8-Ccr5). Unsupervised clustering revealed T-cell effector-rich regions (Tbx21, Cd8a, Prf1) that were nearly exclusive to KO tumors.
Erythroid-specific GARP deletion significantly delayed MB49 tumor growth compared to WT littermates. Adoptive co-transfer of Pmel antigen-specific CD8⁺ T cells with GARP-KO EPCs into WT recipients bearing B16 melanoma confirmed that erythroid GARP is sufficient to suppress anti-tumor T cell responses, and its deletion restores tumor control.
Finally, we identified expanded GARP-expressing CD45+CD235+ EPCs in patients with MPN, and several types of solid tumors, supporting the translational potential of targeting this population.
Conclusions: Erythroid GARP is required for EPC-to-MDSC transdifferentiation via activation of the C/EBPβ program and TGFβ/Smad4 signaling. GARP deletion blocks this conversion, collapses the suppressive niche, and restores CD8+ T cell effector function. Targeting erythroid GARP represents a novel strategy to overcome tumor immunosuppression by interrupting myeloid trans-differentiation at its source.

Maria Velegraki, MD, PhD: No relevant conflicts of interest to declare.